Truist analyst Clarke Murphy initiated coverage of Addus HomeCare (ADUS) with a Buy rating and $135 price target The company is a leader in a “fragmented market with plenty of opportunity,” the analyst tells investors in a research note. The firm says Addus will benefit from secular tailwinds from the more toward alternative sites. It believes the company has a strong earnings outlook with a favorable risk/reward at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus Homecare’s Promising Growth Trajectory: Buy Rating Supported by Strategic Expansion and Rate Increases
- Addus Homecare: Hold Rating Amid CMS Rate Updates and Medicaid Reform Uncertainties
- Buy Rating for Addus Homecare Amid Favorable Adjustments in Home Health Payment System
- BMO Capital Maintains Hold Rating on Addus Homecare Amid Medicaid Funding Concerns and Regulatory Uncertainties
- Addus HomeCare initiated with a Market Perform at BMO Capital